



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BIOMARK DIAGNOSTICS INC. EXPANDS PHASE 3 CLINICAL TRIALS

Vancouver, British Columbia – (November 5, 2014)–BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) is pleased to announce that BioMark has expanded its Phase 3 cancer screening clinical trials to include The National Institute of Cancer Research and Hospital in Bangladesh. The clinical trials are in the process of being registered with both clinicaltrials.gov and the World Health Organization (WHO).

BioMark anticipates completing 50% of the 340 patient Phase 3 clinical trial by the first quarter of 2015. Following a successful completion of the clinical trial and regulatory health approval, BioMark will commence marketing its proprietary technologies in key global markets.

Rashid Ahmed , President & CEO, states: “This is a significant achievement for BioMark. Strong research collaborators such as The National Institute of Cancer Research and Hospital in Bangladesh, in addition to long-term partners such as St-Boniface Hospital Research, CancerCare Manitoba, Surrey Memorial Hospital, have been instrumental in moving our cancer diagnostic technology forward. We look forward to completing our trials in 2015 and to offer diagnostic options that can be used solo or to complement existing cancer detection and treatment technologies.”

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-282-6567

Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Biomark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.